B.A. Biological Sciences, University of Delaware, 2006
Ph.D. Cell and Molecular Biology, University of Pennsylvania, 2013
Postdoctoral Fellowship, Harvard University, 2020


Alexander Valvezan is an Assistant Professor of Pharmacology at the Rutgers Robert Wood Johnson Medical School and Resident Faculty Member in the Center for Advanced Biotechnology and Medicine. Dr. Valvezan completed his PhD at the University of Pennsylvania in the laboratory of Dr. Peter Klein, studying the Wnt signaling pathway in embryonic development and cancer. He then joined the laboratory of Dr. Brendan Manning at Harvard University as a postdoctoral fellow, studying tumor metabolism and the mTOR signaling and metabolic network. Dr. Valvezan’s current research interests focus on understanding how signaling pathways coordinate metabolic networks to promote cell growth, with emphasis on the impact of common oncogenic mutations, and the goal of exploiting unique tumor dependencies for therapeutic benefit.

Research Focus

Signaling and metabolic networks in cell growth and cancer, identifying and exploiting cancer vulnerabilities

Assistant Professor of Pharmacology, RWJMS

Assistant Professor of Medicine, RWJMS

Cancer Institute of New Jersey

2021 Leukemia Research Foundation Research Grant

2020 Rutgers Cancer Institute of New Jersey New Investigator Award

Department of Defense Tuberous Sclerosis Complex Research Program Award


Valvezan A, Turner M, Belaid A, et al. mTORC1 Couples Nucleotide Synthesis to Nucleotide Demand Resulting in a Targetable Metabolic Vulnerability. Cancer cell. 2017;32(5):624-638.e5. doi:10.1016/j.ccell.2017.09.013.
Valvezan A, McNamara M, Miller S, et al. IMPDH inhibitors for antitumor therapy in tuberous sclerosis complex. JCI insight. 2020;5(7). doi:10.1172/jci.insight.135071.
Valvezan A, Manning B. Molecular logic of mTORC1 signalling as a metabolic rheostat. Nature metabolism. 2019;1(3):321-333. doi:10.1038/s42255-019-0038-7.